Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Perioperative Negative Emotions in Breast Cancer Surgery
NCT07367542Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Perioperative anxiety and depression at day 30. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07367542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367542.